摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Oxa-1-aza-bicyclo[3.3.1]non-6-ylamine | 107904-00-7

中文名称
——
中文别名
——
英文名称
4-Oxa-1-aza-bicyclo[3.3.1]non-6-ylamine
英文别名
4-Oxa-1-azabicyclo[3.3.1]nonan-6-amine
4-Oxa-1-aza-bicyclo[3.3.1]non-6-ylamine化学式
CAS
107904-00-7
化学式
C7H14N2O
mdl
MFCD19210712
分子量
142.201
InChiKey
UHRGMJYITZJLGO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.8
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    38.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    The synthesis of 2-morpholine carboxylic acid derivatives and their elaboration to 1-aza-4-oxabicyclo[3.3.1]nonan-6-one.
    摘要:
    Two syntheses of novel 2-morpholine carboxylic acid derivatives are described. The esters were converted into 1-aza-4-oxabicyclo[3.3.1]nonan-6-one, the first example of this ring system, which was further elaborated to the ortho-methoxy benzamide derivative (2).
    DOI:
    10.1016/s0040-4039(00)79702-4
  • 作为产物:
    描述:
    1-aza-4-oxabicyclo<3.3.1>nonan-6-one 在 lithium aluminium tetrahydride 、 盐酸羟胺 作用下, 生成 4-Oxa-1-aza-bicyclo[3.3.1]non-6-ylamine
    参考文献:
    名称:
    The synthesis of 2-morpholine carboxylic acid derivatives and their elaboration to 1-aza-4-oxabicyclo[3.3.1]nonan-6-one.
    摘要:
    Two syntheses of novel 2-morpholine carboxylic acid derivatives are described. The esters were converted into 1-aza-4-oxabicyclo[3.3.1]nonan-6-one, the first example of this ring system, which was further elaborated to the ortho-methoxy benzamide derivative (2).
    DOI:
    10.1016/s0040-4039(00)79702-4
点击查看最新优质反应信息

文献信息

  • Oxa-, thia- and diazabicycloalkane derivatives, process for their preparation and their use as pharmaceuticals
    申请人:BEECHAM GROUP PLC
    公开号:EP0226267A1
    公开(公告)日:1987-06-24
    Compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein: j is 0 or 1; q is 0, 1 or 2; p is 0 and r is 2 or 3, or p is 1 and r is 2; X is 0, S, SO or NR where R is hydrogen, C1-6 alkyl or C1-10 carboxylic acyl; Y is NH; or 0 when R, is hydrogen; either R, is C1-6 alkoxy and one of R2, R3 and R4 is hydrogen and the other two are selected from hydrogen, halogen, CF3, C1-6 alkylthio, C1-7 acyl, C1-10 carboxylic acyiamino, C1-6 alkyl S(O)n wherein n is 0, or 2, nitro or amino, aminocarbonyl or aminosulphonyl optionally substituted by one or two groups selected from C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1-4 alkyl or phenyl C1-4 alkyl groups any of which phenyl moieties may be substituted by one or two groups selected from halogen, CF3, C1-6 alkyl or C1-6 alkoxy; or R, is hydrogen and R2, R3 and R4 are independently selected from hydrogen; C1-6 alkyl. hydroxy, C1-6 alkoxy, C1-6 alkylthio or halo; or any two on adjacent carbon atoms together are C1-2 alkylenedioxy and the third is hydrogen, C1-6 alkyl, C1-6 alkoxy or halo; one of R5 and R6 is hydrogen, C1-6 alkyl, phenyl or phenyl-C1-6 alkyl, which phenyl moieties may be substituted by C1-6 alkyl, C1-6 alkoxy or haiogen; and the other is hydrogen or C1-6 alkyl; and R7 is hydrogen, C, alkyl, phenyl or phenyl-C1-3 alkyl, which phenyl moieties may be substituted by C1-6 alkyl, C1-6 alkoxy, CF3 or halogen having gastric motility enhancing activity, anti-emetic activity and/or 5-HT receptor ant. agonist activity, a process and intermediates for their preparation and their use as pharmaceuticals.
    式 (I) 的化合物或其药学上可接受的盐: 其中 j 为 0 或 1 q 是 0、1 或 2 p 为 0,r 为 2 或 3,或 p 为 1,r 为 2; X 是 0、S、SO 或 NR,其中 R 是氢、C1-6 烷基或 C1-10 羧酰基; 当 R 为氢时,Y 为 NH;当 R 为氢时,Y 为 0;当 R 为 C1-6 烷氧基,且 R2、R3 和 R4 中的一个为氢,另两个选自氢、卤素、CF3、C1-6 烷硫基、C1-7 乙酰基、C1-10 羧酰基氨基、C1-6 烷基 S(O)n 时,Y 为 0。 烷基 S(O)n,其中 n 为 0 或 2;硝基或氨基、氨基羰基或氨基磺酰基,可任选被一个或两个选自 C1-6 烷基、C3-8 环烷基、C3-8 环烷基、C3-8 环烷基 C1-4 烷基或苯基 C1-4 烷基的基团取代,其中任何苯基基团可被一个或两个选自卤素、CF3、C1-6 烷基或 C1-6 烷氧基的基团取代;或 R 为氢,R2、R3 和 R4 独立选自氢、C1-6 烷基R5和R6中的一个是氢、C1-6烷基、苯基或苯基-C1-6烷基,其中苯基可被C1-6烷基、C1-6烷氧基或硫代卤素取代;另一个是氢或C1-6烷基。 R7 是氢、C、烷基、苯基或苯基-C1-3 烷基,其中苯基可被 C1-6 烷基、C1-6 烷氧基、CF3 或卤素取代,具有胃动力增强活性、止吐活性和/或 5-HT 受体拮抗剂活性,以及制备它们的工艺和中间体及其作为药物的用途。
  • US4826839A
    申请人:——
    公开号:US4826839A
    公开(公告)日:1989-05-02
  • US4883874A
    申请人:——
    公开号:US4883874A
    公开(公告)日:1989-11-28
  • US5530120A
    申请人:——
    公开号:US5530120A
    公开(公告)日:1996-06-25
  • US5561139A
    申请人:——
    公开号:US5561139A
    公开(公告)日:1996-10-01
查看更多